SCHEMBL30765442

SCHEMBL30765442

CC(=O)OCC(=O)Nc1ccc(-c2ncc(NCc3ccc4oc5ccccc5c4c3)c(=O)n2CC(=O)OC(C)(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 6/20 0.38
NPSR1 Q6W5P4 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
LMNA P02545 3/20 0.36
TP53 P04637 3/20 0.36
ALOX15 P16050 1/20 0.36
MAPT P10636 5/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 3/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
CETP P11597 1/20 0.35
ESR1 P03372 1/20 0.35
POLB P06746 1/20 0.35
NPY1R P25929 1/20 0.35
NPY2R P49146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765547 0.91 TDP1 (0.40) ELANENPSR1TDP1RXFP1LMNA
SCHEMBL30765921 0.89 GAA (0.42) ELANENPSR1TDP1RXFP1LMNA
SCHEMBL30765948 0.83 LMNA (0.39) ELANENPSR1RXFP1LMNAPOLB
SCHEMBL30765784 0.82 NPSR1 (0.35) ELANENPSR1TDP1RXFP1LMNA
SCHEMBL30765845 0.82 TDP1 (0.36) ELANENPSR1TDP1LMNATP53
SCHEMBL30765705 0.79 ALDH1A1 (0.38) NPSR1TDP1RXFP1LMNATP53
SCHEMBL30766060 0.79 BCHE (0.33) NPSR1RXFP1LMNAMAPTKMT2A
SCHEMBL30765926 0.78 GAA (0.52) ELANELMNATP53MAPTMEN1
SCHEMBL30765838 0.77 CASP1 (0.41) ELANELMNAHPGDKDM4EPOLB
SCHEMBL30765777 0.77 HCRTR1 (0.40) ELANENPSR1TDP1RXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed